Spiriva Respimat | Boehringer Ingelheim | UK | tiotropium

This is a promotional website intended for UK healthcare professionals only. Not a healthcare professional? Visit our Public site.

SPIRIVA® Respimat® in asthma

Information about using SPIRIVA® Respimat® add-on therapy for your adult asthma patients who remain symptomatic on ICS/LABA.

SPIRIVA® Respimat® (tiotropium) is indicated in the UK* as an add-on maintenance bronchodilator treatment for adult patients with asthma who are currently treated with the maintenance combination of inhaled corticosteroids (≥800 μg budesonide/day or equivalent) and long-acting β2 agonists and who experienced one or more severe exacerbations in the previous year.

*SPIRIVA® Respimat® is also indicated as a maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (COPD).

Product information

This section describes the mechanism of action (MoA) of SPIRIVA® Respimat®, and provides information about its efficacy and safety as well as instructions about dosing & administration via the Respimat® inhaler.


Frequently Asked Questions cover a wide range of subjects, including evidence from the SPIRIVA® Respimat® clinical trial programme, prescribing guidelines for SPIRIVA®  Respimat®, and the administration of SPIRIVA® via the Respimat® inhaler.